<DOC>
	<DOC>NCT00996983</DOC>
	<brief_summary>Neuropathic pain is difficult to control because it is only partially sensitive to opioid analgesics, and requires the addition of other therapies such as antidepressants and epileptics. Ziconotide is a drug that is used to treat neuropathic pain in patients who have had inadequate pain control with prior combination of medicines.</brief_summary>
	<brief_title>Safety and Activity Study of Intrathecally Administered Ziconotide for Neuropathic Pain in Patients With Cancer</brief_title>
	<detailed_description>The purpose of this study is to evaluate the effects and the tolerability of intrathecal ziconotide in cancer patients suffering from severe neuropathic pain not controlled by previous therapies.</detailed_description>
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Pain, Intractable</mesh_term>
	<mesh_term>Ziconotide</mesh_term>
	<mesh_term>omega-Conotoxins</mesh_term>
	<criteria>Diagnosis of neoplasm Neuropathic pain level VASPI &gt; or = 6 (010 scale) Inadequate pain relief with opioid analgesics and adjuvants Age &gt; or = 18 years Performance status ECOG 02 Life expectancy at least one month Adequate contraception in women of childbearing potential Signed Informed Consent Use of experimental drugs within previous 30 days Pregnancy or lactation Contraindication to the use of intrathecal analgesics, including active infection or conditions that could alter the circulation of cerebrospinal fluid Presence of cerebral metastasis INR &gt; 2 Contraindication to the use of ziconotide Unable or unwilling to provide informed consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>